Why the study?
The study was conducted to evaluate platelet hemostasis parameters and antiplatelet efficacy on day 1 of cardioembolic stroke in patients with AF with or without pre-stroke warfarin use.
Does prior warfarin use alter platelet hemostasis parameters in patients with cardioembolic stroke and atrial fibrillation?
Observational (n=93)
No
Does prior warfarin use alter platelet hemostasis parameters in patients with cardioembolic stroke and atrial fibrillation?
p-value: p=0.047
Patients with cardioembolic stroke and atrial fibrillation who previously took warfarin exhibit altered platelet aggregation profiles, suggesting additional risk factors for recurrent strokes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Galkin et al. (2021) conducted an observational in Cardioembolic stroke with atrial fibrillation (n=93). Prior warfarin use vs. No prior warfarin use was evaluated on Spontaneous platelet aggregation (p=0.047).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: